Lv11
40 积分 2026-09-19 加入
Lurbinectedin in the therapeutic landscape of SCLC: Key clinical evidence and evolving role in the era of emerging therapies
2个月前
已完结
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
2个月前
已完结
XPO1-mediated TRIM21 nuclear export reprograms TREM2+ macrophage polarization by targeting IRF3 to augment anti-PD-1 efficacy in small cell lung cancer
2个月前
已完结
A blood-brain barrier-like vascular gate limits immunotherapy efficacy in neuroendocrine cancers
2个月前
已完结
MA11.04 Safety of Lurbinectedin + Atezolizumab as 1L Maintenance Treatment in ES-SCLC: Results From the Phase 3 IMforte Study
2个月前
已关闭
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
2个月前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
2个月前
已完结
The efficacy and safety of immune checkpoint inhibitor in patients with relapsed small-cell lung cancer: A systematic review and meta-analysis
2个月前
已完结
Systematic review and network meta-analysis: evaluation of systemic therapies for platinum refractory or resistant small cell lung cancer
2个月前
已完结
Current and Emerging Treatment Options for Patients With Relapsed Small-cell Lung Carcinoma: A Systematic Literature Review
2个月前
已完结